弥漫性恶性间皮瘤的化疗。单药5-氟尿嘧啶和阿霉素的II期试验。

Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.

作者信息

Harvey V J, Slevin M L, Ponder B A, Blackshaw A J, Wrigley P F

出版信息

Cancer. 1984 Sep 15;54(6):961-4. doi: 10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b.

DOI:10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b

Abstract

Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single-agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months was seen. It is concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second-line agent.

摘要

在一项关于单药5-氟尿嘧啶的II期试验中，对20例确诊为胸膜或腹膜弥漫性恶性间皮瘤且此前未接受过化疗的连续患者进行了研究。观察到1例持续24个月的部分缓解。11例患者在5-氟尿嘧啶治疗进展后接受了单药阿霉素（多柔比星）治疗，观察到1例持续34个月的部分缓解。得出的结论是，5-氟尿嘧啶在弥漫性恶性间皮瘤中仅有极小的活性。初步数据表明，阿霉素作为二线药物活性很小。